Alberta has been attracting investment recently.
The province garnered more venture capital than British Columbia for the first time.
Alberta’s success that quarter was largely powered by energy technology company ClearSky Global, who provided a major boost to the province’s numbers thanks to a raise of more than $200M in June.
That kind of capital raise “doesn’t happen every quarter,” we wrote at the time—or does it?
Reinforcing signs that Calgary is increasingly a magnet for investment, Neo Financial secured a $360 million Series D fundraising round consisting of $110 million of equity and $250 million of debt (among other 2024 achievements).
Other investment rounds since then include Calgary-born atVenu’s $179 million equity investment from Sixth Street Growth in October, and a November seed round for Lightstrike, a startup specializing in application dependency management.
Even more recently, Calgary-born fintech OneVest secured $27 million in Series B funding just last month to enhance its wealth management technology platform.
One breakthrough field seeing strong investment in Alberta is the medical devices space.
Technology is changing healthcare worldwide, with Canadian entities among the forefront of innovation in the field.
In 2024, Alberta’s medical device industry achieved a record-breaking year for investment, according to the Start Alberta deal flow database.
The banner year was powered by five companies collectively raising $56.6 million in publicly disclosed funding rounds, including Syantra securing $4.9M in Series A capital in September—the same month that Google-accelerated PulseMedica confirmed $12M of its own Series A funding.
Nimble Science, which raised US$1.4M in seed financing in 2024, was also Google-accelerated. Nimble Science’s consumer-friendly capsule finally enables small intestine multi-omic microbiome data collection, empowering novel diagnostic development products.
Before that, RetinaLogik revealed US$780K in seed funding in March.
Launched in 2021, the startup combines artificial intelligence and virtual reality technologies into a software platform that enables visual field tests with a VR headset.
Fluid Biomed, a clinical-stage medical device company specializing in vascular disease treatments, announced the successful closure of a US$27 million Series A equity financing round in December.
The funding will support the development and expanded clinical trials of the ReSolv stent, a groundbreaking bioabsorbable polymer-based stent designed to treat brain aneurysms.
Developed by co-founders Dr. John Wong and Dr. Alim Mitha—both academic neurosurgeons at the University of Calgary—the stent represents a major leap forward in medical technology for addressing one of the leading causes of stroke and disability.
Other regional innovators in the space include Neuraura, Kent Imaging, Rehabtronics, NanoTess, and Tevosol.
Leave a Reply